EGT 022

Drug Profile

EGT 022

Alternative Names: EG 22; EG-Decorin; EG-Mirotin; EGT022; HU-005

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EyeGene
  • Developer EyeGene; Huons
  • Class Membrane proteins; Recombinant proteins
  • Mechanism of Action Angiogenesis inducing agents; Platelet derived growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic retinopathy
  • Phase I/II Pressure ulcer
  • Preclinical Diabetic foot ulcer; Retinopathy of prematurity

Most Recent Events

  • 15 Aug 2017 Phase-II clinical trials in Diabetic retinopathy in Hungary (SC) (EudraCT2014-001351-23)
  • 04 May 2016 EGT 022 is still in phase I/II trials for Pressure ulcer in South Korea (Topical)
  • 04 Feb 2014 EGT 022 is available for licensing as of 01 Jan 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top